Trial reportVascular medicine (London, England)2019
A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.
Trial report in Vascular medicine (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2024Pooled it
- A Systematic Review of Interleukins as Diagnostic and Prognostic Biomarkers for Peripheral Artery Disease.Biomolecules · 2023Pooled it
- Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications.Biomolecules · 2026Review
- Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions.Annals of medicine and surgery (2012) · 2026Article
- Peripheral artery disease in diabetes.Frontiers in endocrinology · 2026Review
- Implications of inflammation and sex in lower extremity arterial disease.European journal of clinical investigation · 2026Review
- Single-cell compendium of muscle microenvironment in peripheral artery disease reveals altered endothelial diversity and LYVE1Nature cardiovascular research · 2025Article
- Peripheral artery disease.Nature reviews. Disease primers · 2025Review
- Coronary Artery Disease and Atherosclerosis in Other Vascular Districts: Epidemiology, Risk Factors and Atherosclerotic Plaque Features.Life (Basel, Switzerland) · 2025Review
- Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Leukotrienes E4 and B4 and vascular endothelium - New insight into the link between vascular inflammation and peripheral arterial.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Characteristics, Antithrombotic Patterns, and Prognostic Outcomes in Claudication and Critical Limb-Threatening Ischemia Undergoing Endovascular Therapy.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2024Observational
- Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach.International journal of molecular sciences · 2024Review
- The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases.Nature reviews. Cardiology · 2024Review
- Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies.Pharmaceutics · 2024Review
- Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study.Frontiers in cardiovascular medicine · 2024Article
- Manifestations of human atherosclerosis across vascular beds.JVS-vascular insights · 2024Article
- Magnetic Resonance Imaging Techniques in Peripheral Arterial Disease.Advances in wound care · 2023Review
- Circulating Soluble EPCR Levels Are Reduced in Patients with Ischemic Peripheral Artery Disease and Associated with Markers of Endothelial and Vascular Function.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 2 countries.
Funding
Abstract
Extensive atherosclerotic plaque burden in the lower extremities often leads to symptomatic peripheral artery disease (PAD) including impaired walking performance and claudication. Interleukin-1β (IL-1β) may play an important pro-inflammatory role in the pathogenesis of this disease. Interruption of IL-1β signaling was hypothesized to decrease plaque progression in the leg macrovasculature and improve the mobility of patients with PAD with intermittent claudication. Thirty-eight patients (mean age 65 years; 71% male) with symptomatic PAD (confirmed by ankle-brachial index) were randomized 1:1 to receive canakinumab (150 mg subcutaneously) or placebo monthly for up to 12 months. The mean vessel wall area (by 3.0 T black-blood magnetic resonance imaging (MRI)) of the superficial femoral artery (SFA) was used to measure plaque volume. Mobility was assessed using the 6-minute walk test. Canakinumab was safe and well tolerated. Markers of systemic inflammation (interleukin-6 and high-sensitivity C-reactive protein) fell as early as 1 month after treatment. MRI (32 patients at 3 months; 21 patients at 12 months) showed no evidence of plaque progression in the SFA in either placebo-treated or canakinumab-treated patients. Although an exploratory endpoint, placebo-adjusted maximum and pain-free walking distance (58 m) improved as early as 3 months after treatment with canakinumab when compared with placebo. Although canakinumab did not alter plaque progression in the SFA, there is an early signal that it may improve maximum and pain-free walking distance in patients with symptomatic PAD. Larger studies aimed at this endpoint will be required to definitively demonstrate this.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.